BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
BioAge Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.99+0.15 (+3.10%)
Close on Oct 19, 2026
- Market cap
- $223.75M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.19 (−3.67%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BioAge Labs, Inc. grew revenue 168.1% to $10.36M over the twelve months to Jun 30, 2026. Free cash flow was -$88.09M.
Revenue
$10.36M
+168.1% vs. a year earlier
Operating income
-$106.27M
TTM Q2 2026
Free cash flow
-$88.09M
TTM Q2 2026
EPS, diluted
-$2.38
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $223.75M
- P/E ratio
- –
- Price to sales
- 21.61
- Price to book
- 0.60
- Dividend yield
- –
- Free cash flow yield
- -39.37%
Fundamentals
- Revenue
- $10.36M
- Net income
- -$94.46M
- EPS, diluted
- -$2.38
- Free cash flow
- -$88.09M
- Book value per share
- $8.36
- Diluted shares
- 45M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$10.36M+168.1% YoY
Operating income
-$106.27M
Net income
-$94.46M
EPS, diluted
-$2.38
Free cash flow
-$88.09M
Reported periodTrailing twelve months